Copyright
©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1178-1193
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1178
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1178
Drug class | Drug | Dosing |
Insulin | ||
Rapid-acting insulin | Insulin lispro | First trimester 0.7 units/kg/d. 14-18 wk 0.8 units/kg/d. 26-27 wk 0.9 units/kg/d. 36-37 wk until delivery 1 unit/kg/d[95] |
Insulin aspart | ||
Short-acting insulin | Regular insulin | First trimester 0.7 units/kg/d. 14-18 wk 0.8 units/kg/d. 26-27 wk 0.9 units/kg/d. 36-37 wk until delivery 1 unit/kg/d[95] |
Intermediate-acting insulin | NPH | Two thirds can be given prebreakfast and the remaining one third can be given during the pre-evening meal[95] |
Long-acting insulin | Detemir | 50% of total daily dose can be given in the pre-evening meal and the remaining 50% can be given as a basal insulin[95] |
Glargine | ||
Oral agents | ||
Biguanide | Metformin | 500 mg once or twice daily with an increase over 1 to 2 wk to a maximum daily dose of 2500 mg. 2000 mg if using metformin of extended release[90,92] |
Sulfonylurea | Glyburide | Starting dose of 2.5 to 5 mg once daily with an increase to a maximum dose of 20 mg/d[96] |
- Citation: Mendez Y, Alpuing Radilla LA, Delgadillo Chabolla LE, Castillo Cruz A, Luna J, Surani S. Gestational diabetes mellitus and COVID-19: The epidemic during the pandemic. World J Diabetes 2023; 14(8): 1178-1193
- URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1178.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i8.1178